Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1

Conditions

Breast Neoplasms 300Carcinoma, Non-Small-Cell Lung 225Neoplasms 195Prostatic Neoplasms 164Multiple Myeloma 139Neoplasm Metastasis 117Melanoma 113Colorectal Neoplasms 108Leukemia, Myeloid, Acute 107Lung Neoplasms 98Lymphoma 97Ovarian Neoplasms 87Squamous Cell Carcinoma of Head and Neck 77Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 65Triple Negative Breast Neoplasms 64Pancreatic Neoplasms 64Hematologic Neoplasms 60Parkinson Disease 4, Autosomal Dominant Lewy Body 59Head and Neck Neoplasms 59Glioblastoma 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Recurrence 56Leukemia 56Sarcoma 50Brain Neoplasms 50Lymphoma, Large B-Cell, Diffuse 48Carcinoma, Hepatocellular 47Lymphoma, Follicular 46

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma, Alveolar × 1 year × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡